Best Penny Stocks Under $1.00 Right Now

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. While stocks are no longer hitting new all-time highs, the price-to-earnings ratios of most S&P 500 companies still look somewhat expensive historically speaking. Many investors are having trouble finding low-priced stocks that have great business fundamentals and actually generate cash flow.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 20 times their annual earnings. While the stock market is more expensive as a whole than it has been historically, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks, and biotechnology stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 (1 dollar) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

#1 - Enthusiast Gaming

NASDAQ:EGLX
Stock Price: $0.41 (-$0.01)
PE Ratio: -1.08
Market Cap: $64.79 million
Average Trading Volume: 140,811 shares
Consensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.20 (918.9% Upside)

Enthusiast Gaming Holdings Inc., an integrated gaming entertainment company, engages in the media, content, entertainment, and esports businesses in Canada, the United States, England and Wales, and internationally. The company owns and operates video-gaming expo; owns and manages esports teams for various games comprising Apex Legends, Rocket League, World of Warcraft, Call of Duty: Mobile, Rainbow Six Siege, PlayerUnknown's Battlegrounds, Call of Duty: Warzone, Super Smash Bros: Melee, and Super Smash Bros: Ultimate; and produces and programs approximately 20 weekly shows across advertising-based video on demand (AVOD) and over-the-top (OTT) channels, as well as represents approximately 500 gaming influencers on YouTube and Twitch. It also owns and operates approximately 50 websites that contain news, reviews, videos, live streams, blog posts, tips, chats, message boards, other video-gaming related content, and casual games. In addition, the company operates Luminosity Gaming, an eSports organization; operates approximately 25 video game networking events; and hosts B2B and consumer mobile gaming events. Enthusiast Gaming Holdings Inc. is headquartered in Toronto, Canada.

#2 - Fortress Biotech

NASDAQ:FBIO
Stock Price: $0.59 (+$0.01)
PE Ratio: -0.59
Market Cap: $77.91 million
Average Trading Volume: 926,937 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.50 (839.5% Upside)

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

#3 - Leap Therapeutics

NASDAQ:LPTX
Stock Price: $0.62 (-$0.06)
PE Ratio: -0.87
Market Cap: $80.59 million
Average Trading Volume: 1.74 million shares
Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.80 (355.3% Upside)

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

#4 - Passage Bio

NASDAQ:PASG
Stock Price: $0.96 (-$0.02)
PE Ratio: -0.41
Market Cap: $53.64 million
Average Trading Volume: 111,135 shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.80 (815.7% Upside)

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

#5 - Saipem

OTCMKTS:SAPMY
Stock Price: $0.27
PE Ratio: 0.83
Average Trading Volume: 44,547 shares
P/E Ratio: 0.8
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $1.95 (633.1% Upside)

Saipem SpA provides energy and infrastructure solutions worldwide. The company operates through divisions Offshore Engineering & Construction (E&C), Onshore Engineering & Construction, and Offshore Drilling. It offers development of subsea fields and pipelaying; installation and lifting of offshore structures; and engineering, implementation, installation, maintenance, modification, and decommissioning activities. The company also provides biorefineries, geothermal energy, carbon capture, wind and solar energy, waste to energy, and renewables and green technologies; high-speed rail; premium, engineering, and smart maintenance services; and offshore and onshore services. In addition, the company provides procurement, project management, construction, and engineering integrated services for the energy industry and public markets. Saipem S.p.A. was founded in 1957 and is headquartered in Milan, Italy.

#6 - Argonaut Gold

OTCMKTS:ARNGF
Stock Price: $0.44 (-$0.02)
PE Ratio: -5.72
Average Trading Volume: 429,435 shares
Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $1.00 (129.6% Upside)

Argonaut Gold, Inc. engages in the exploration, mine development, and production activities on gold-bearing properties. Its primary assets are the production stage El Castillo mine and San Agustin mine, which together form the El Castillo Complex in Durango, Mexico and the production stage La Colorada mine in Sonora, Mexico. The company was founded on April 3, 2007 and is headquartered in Reno, NV.

#7 - Affimed

NASDAQ:AFMD
Stock Price: $0.71 (+$0.01)
PE Ratio: -1.01
Market Cap: $106.02 million
Average Trading Volume: 1.02 million shares
Consensus Rating: Buy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.50 (674.8% Upside)

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

#8 - Greenbrook TMS

NASDAQ:GBNH
Stock Price: $0.72 (-$0.03)
PE Ratio: -0.29
Market Cap: $13.35 million
Average Trading Volume: 34,242 shares
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.06 (603.1% Upside)

Greenbrook Tms, Inc. engages in the control and operation of a network of outpatient mental health services centers that specialize in the provision of Transcranial Magnetic Stimulation (TMS) therapy and other treatment modalities for the treatment of depression and related psychiatric services. The company was founded on February 9, 2018 and is headquartered in Toronto, Canada.

#9 - Local Bounti

NYSE:LOCL
Stock Price: $0.37
PE Ratio: -0.31
Market Cap: $39.07 million
Average Trading Volume: 196,009 shares
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.65 (620.7% Upside)

Local Bounti Corporation grows fresh greens and herbs in the United States. It produces lettuce, herbs, and loose-leaf lettuce. The company sells its products to food retailers and food service distributors. Local Bounti Corporation was founded in 2018 and is headquartered in Hamilton, Montana.

#10 - Adaptimmune Therapeutics

NASDAQ:ADAP
Stock Price: $0.99 (-$0.02)
PE Ratio: -1.43
Market Cap: $152.71 million
Average Trading Volume: 703,519 shares
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.12 (519.8% Upside)

Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the provision and development of novel cell therapies and novel cancer immunotherapy products to people with cancer. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

#11 - AgileThought

NASDAQ:AGIL
Stock Price: $0.80 (+$0.01)
PE Ratio: -0.72
Market Cap: $39.49 million
Average Trading Volume: 63,702 shares
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.80 (625.7% Upside)

AgileThought, Inc. provides digital transformation services in the United States and Latin America. It offers organizational transformations, training and certifications, and product management services. The company provides application engineering and DEVOPS, cloud architecture and migration, data analytics, automation, application modernization, UX/UI design, artificial intelligence, and machine learning services. In addition, it offers lifecycle management support and multi cloud services. The company serves professional services, healthcare, pharmacy, financial services, energy, and utilities industries. AgileThought, Inc. was founded in 2000 and is headquartered in Irving, Texas.

#12 - Monopar Therapeutics

NASDAQ:MNPR
Stock Price: $0.94 (+$0.02)
PE Ratio: -1.15
Market Cap: $12.16 million
Average Trading Volume: 799,674 shares
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $11.33 (1,105.7% Upside)

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

#13 - Science 37

NASDAQ:SNCE
Stock Price: $0.30 (+$0.03)
PE Ratio: -0.29
Market Cap: $31.52 million
Average Trading Volume: 278,289 shares
Consensus Rating: Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.50 (1,075.3% Upside)

Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.

#14 - Assura

OTCMKTS:ARSSF
Stock Price: $0.65
Average Trading Volume: 7,412 shares
Consensus Rating: Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $64.67 (9,861.0% Upside)

Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create outstanding spaces for health services in our communities. At 30 September 2020, Assura's property portfolio was valued at £2,259 million.

#15 - Taysha Gene Therapies

NASDAQ:TSHA
Stock Price: $0.86 (+$0.02)
PE Ratio: -0.31
Market Cap: $54.10 million
Average Trading Volume: 255,364 shares
Consensus Rating: Buy (10 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.23 (857.1% Upside)

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

#16 - Harpoon Therapeutics

NASDAQ:HARP
Stock Price: $0.73 (-$0.04)
PE Ratio: -0.42
Market Cap: $24.72 million
Average Trading Volume: 163,952 shares
Consensus Rating: Buy (5 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.71 (544.0% Upside)

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

#17 - Motus GI

NASDAQ:MOTS
Stock Price: $0.74 (+$0.02)
PE Ratio: -0.14
Market Cap: $3.47 million
Average Trading Volume: 930,794 shares
Consensus Rating: Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.81 (680.3% Upside)

Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in September, 2016 and is headquartered in Fort Lauderdale, FL.

#18 - WeWork

NYSE:WE
Stock Price: $0.18
PE Ratio: -0.08
Market Cap: $392.31 million
Average Trading Volume: 13.12 million shares
Consensus Rating: Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.83 (2,519.4% Upside)

WeWork Inc. provides flexible workspace solutions to individuals and organizations worldwide. The company offers workstation, private office, and customized floor solutions; and various amenities and services, such as private phone booths, internet, high-speed business printers and copiers, mail and package handling, front desk services, off-peak building access, common areas, and daily enhanced cleaning solutions. It also offers various value-add services; business and technical service solutions, including professional employer organization and payroll services, remote workforce solutions, human resources benefits, dedicated bandwidth, and IT equipment co-location solutions. In addition, the company offers workspace management solutions, which enable landlords and operators to power flexible spaces and provide direct access to an established customer base. As of December 31, 2021, its real estate portfolio includes 756 locations. WeWork Inc. was founded in 2010 and is headquartered in New York, New York.

#19 - Spire Global

NYSE:SPIR
Stock Price: $0.72 (+$0.01)
PE Ratio: -1.05
Market Cap: $104.55 million
Average Trading Volume: 717,616 shares
Consensus Rating: Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.06 (184.5% Upside)

Spire Global, Inc. provides subscription-based data, insights, predictive analytics, and related project-based services worldwide. The company offers satellite-based aircraft tracking data to power applications, drive decision making, and improve cost efficiencies; data, insights, and predictive analytics for highly accurate ship monitoring, real-time and near real-time vessel updates, port operations, ship safety and route optimization; and space-based data, AI-powered insights, and predictive weather analytics for accurate weather forecasting. It serves maritime, weather, aviation, space services, earth intelligence, and federal industries. Spire Global, Inc. was formerly known as Nanosatisfi, Inc. and changed its name to Spire Global, Inc. in July 2014. The company is headquartered in Vienna, Virginia.

#20 - LumiraDx

NASDAQ:LMDX
Stock Price: $0.42 (-$0.02)
PE Ratio: -0.28
Market Cap: $133.79 million
Average Trading Volume: 174,904 shares
Consensus Rating: Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.14 (408.9% Upside)

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.

#21 - Marathon Gold

OTCMKTS:MGDPF
Stock Price: $0.58 (-$0.02)
Average Trading Volume: 181,174 shares
Consensus Rating: Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.18 (278.3% Upside)

Marathon Gold Corp. engages in the acquisition, exploration, and development of precious and base metal prospects. It also focuses on Valentine Gold Project located in Newfoundland and Labrador. The company was founded on December 3, 2009 and is headquartered in Toronto, Canada.

#22 - Ayr Wellness

OTCMKTS:AYRWF
Stock Price: $0.88 (-$0.01)
PE Ratio: -0.14
Market Cap: $56.66 million
Average Trading Volume: 246,548 shares
Consensus Rating: Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $12.00 (1,268.3% Upside)

Ayr Wellness Inc., a vertically-integrated cannabis multi-state operator, cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. The company's cannabis and cannabis products include concentrates, edibles, and vaporizers. It also provides administrative, consulting, and operations support services to licensed cannabis companies. As of November 1, 2022, Ayr Wellness Inc. operated 52 dispensaries. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.

#23 - Signature Bank

NASDAQ:SBNY
Stock Price: $0.13 (+$0.01)
PE Ratio: 0.01
Market Cap: $7.55 million
Average Trading Volume: 1.30 million shares
P/E Ratio: 0.0
Dividend Yield: 2,333.33%
Consensus Rating: Buy (7 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $174.53 (134,156.4% Upside)

Signature Bank engages in the provision of commercial banking services. It operates through the Commercial Banking and Specialty Finance segments. The Commercial Banking segment consists of commercial real estate lending, commercial and industrial lending, and commercial deposit gathering activities. The Specialty Finance segment consists of financing and leasing products. The company was founded by John Tamberlane, Scott Aaron Shay, and Joseph J. DePaolo in September 2000 and is headquartered in New York, NY.

#24 - REE Automotive

NASDAQ:REE
Stock Price: $0.40 (-$0.01)
PE Ratio: -1.01
Market Cap: $131.02 million
Average Trading Volume: 369,190 shares
Consensus Rating: Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.63 (817.7% Upside)

REE Automotive Ltd. operates in the e-mobility business. The company develops REEcorner technology, which integrates vehicle drive components, including steering, braking, suspension, powertrain, and control into the arch of the wheel. The company also develops REEboard, a flat and modular EV chassis. The company is headquartered in Herzliya, Israel.

#25 - Village Farms International

NASDAQ:VFF
Stock Price: $0.70
PE Ratio: -0.63
Market Cap: $77.17 million
Average Trading Volume: 547,443 shares
Consensus Rating: Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.04 (334.9% Upside)

Village Farms International, Inc., together with its subsidiaries, produces, markets, and distributes greenhouse-grown tomatoes, bell peppers, and cucumbers in North America. It operates through four segments: Produce, Cannabis-Canada, Cannabis-U.S., and Energy. The company also owns and operates a power plant that generates and sells electricity, and provides thermal heat to British Columbia Hydro and Power Authority; produces and supplies cannabis products to other licensed providers and provincial governments in Canada and internationally; and develops and sells cannabinoid-based health and wellness products, including ingestible, edibles, and topical applications. It markets and distributes its products under the Village Farms brand name to retail supermarkets and fresh food distribution companies, as well as products produced under exclusive arrangements with other greenhouse producers. The company was formerly known as Village Farms Canada Inc. and changed its name to Village Farms International, Inc. in December 2009. Village Farms International, Inc. was founded in 1989 and is headquartered in Delta, Canada.

More Stock Ideas from MarketBeat

Stock Lists:

Cheap Stocks:

Stocks By Exchange:

Latest Stock Ideas:

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial